Calistoga Pharmaceuticals Initiates First Oncology Clinical Trial Of Novel PI3K Delta Inhibitor, CAL-101

July 14th, 2008 | Category: Cancer

Calistoga Pharmaceuticals, Inc., a company committed to developing innovative medicines for the treatment of cancer and inflammatory diseases, announced the initiation of a Phase 1 clinical trial of its lead compound, CAL-101, a small molecule phosphoinositide-3 kinase

(PI3K) delta inhibitor, in patients with hematologic cancer. “We at Calistoga are very pleased to be entering our first oncology trial.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Semafore Pharmaceuticals Reports Positive Interim Results From A Phase I Study Of SF1126, A Targeted Pan-PI3K Inhibitor
  • Semafore And Multiple Myeloma Research Consortium (MMRC) Dose First Patient In Phase I Study Of Targeted PI3 Kinase (PI3K) Inhibitor
  • Nereus Pharmaceuticals Initiates Combination Clinical Trial For Proteasome Inhibitor NPI-0052 In Solid Tumors
  • Positive Trial Results–Novel Triple VEGF-R Inhibitor - 100% Of Renal Cell Patients Achieved Partial Response Or Stable Disease
  • Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra(TM) Clinical Trial In Neuroblastoma Patients

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.